COST-EFFECTIVENESS OF ETANERCEPT AND EFALIZUMAB IN THE MANAGEMENT OF MODERATE AND SEVERE PLAQUE PSORIASIS

被引：0
|
作者：
Ortonne, J. P. [1 ]
Feneron, D. [2 ]
Daures, J. P. [3 ]
Ollivier, A. L. [4 ]
Thiriet, C. [4 ]
Maurel, F. [2 ]
Le Pen, C. [5 ]
机构：
[1] Hop Archet 2, Nice, France
[2] IMS Hlth, Puteaux La Defense, France
[3] CHU Nimes, Nimes, France
[4] Wyeth Pharmaceut, Paris, France
[5] Univ Paris 09, Paris, France
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)67017-9
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A617 / A617
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of apremilast in moderate to severe psoriasis in the UK
    Mughal, Farhan
    Barker, Jonathan
    Cawston, Helene
    Damera, Vidya
    Bewley, Anthony
    Morris, James
    Shaw, Tim
    Tencer, Tom
    Zhang, Frank
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB243 - AB243
  • [22] Cost-effectiveness of treatment for moderate-to-severe psoriasis
    Hankin, CS
    Feldman, SR
    Pearce, D
    VALUE IN HEALTH, 2004, 7 (06) : 654 - 654
  • [23] The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis
    Rouse, Nicole C.
    Farhangian, Michael E.
    Wehausen, Brooke
    Feldman, Steven R.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (06) : 877 - 884
  • [24] COST-EFFECTIVENESS OF BIOLOGIC TREATMENTS FOR MODERATE TO SEVERE PSORIASIS
    Carretero, G.
    Moreno, J. C.
    Notario, J.
    Silvestre, J. F.
    Lopez-Belmonte, J. L.
    Gimenez, E.
    Sabater, F. J.
    Fonseca, E.
    VALUE IN HEALTH, 2009, 12 (07) : A457 - A457
  • [25] Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis
    Papp, KA
    Miller, B
    Gordon, KB
    Caro, I
    Kwon, P
    Compton, PG
    Leonardi, CL
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (04) : S164 - S170
  • [26] Efalizumab A Review of its Use in the Management of Chronic Moderate-to-Severe Plaque Psoriasis
    Frampton, James E.
    Plosker, Greg L.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2009, 10 (01) : 51 - 72
  • [27] Cost-effectiveness of apremilast in moderate-to-severe chronic plaque psoriasis: a model analysis in the UK
    Mughal, F.
    Barker, J.
    Cawston, H.
    Damera, V.
    Bewley, A.
    Morris, J.
    Shaw, T.
    Tencer, T.
    Zhang, F.
    BRITISH JOURNAL OF DERMATOLOGY, 2016, 175 : 74 - 74
  • [28] COST-EFFECTIVENESS ANALYSIS OF USTEKINUMAB COMPA RED WITH ETANERCEPT FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN COSTA RICA
    Obando, C. A.
    Desanvicente-Celis, Z.
    Herrera, J. A.
    Moreira, M.
    De Castro, J.
    VALUE IN HEALTH, 2014, 17 (07) : A607 - A607
  • [29] Efficacy and safety of etanercept in moderate to severe plaque psoriasis
    Tunca, M.
    Koc, E.
    Akar, A.
    Kurumlu, Z.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2007, 21 : 53 - 53
  • [30] Cost Effectiveness of Moderate to Severe Psoriasis Therapy with Etanercept and Ustekinumab in the United States
    Villacorta, Reginald
    Hay, Joel W.
    Messali, Andrew
    PHARMACOECONOMICS, 2013, 31 (09) : 823 - 839
12345